CSIMarket
 

Ceribell Inc   (NASDAQ: CBLL)

Ceribell Inc 's

Competitiveness




 

CBLL Sales vs. its Competitors Q2 2026







Revenue Growth Comparisons




Net Income Comparison




<<  CBLL Stock Performance Comparisons


Ceribell Inc 's Comment on Competition and Industry Peers


The company operates in the competitive market for EEG alternatives, primarily competing against conventional EEG systems commonly used in U.S. hospitals. Key competitors include Natus and Nihon Kohden, both of which have longer operating histories, greater brand recognition, larger market shares, more resources, stronger financial positions, and larger sales forces. The company also faces competition from firms developing rapid EEG systems for acute care and other settings such as home and ambulance use, including Natus and Nihon Kohden. Competitors may offer similar or superior products at more competitive prices and may be better positioned to serve customers.



*Market share is calculated based on total revenue.





Publicly Traded Peers of Ceribell Inc



Sources: Ceribell Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Ceribell Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.